logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

METALIGHT (02605.HK) will be IPO from June 2nd to June 5th, with a plan to globally issue 24.856 million shares.

date
03/06/2025
Financial APP News, METALIGHT (02605.HK) will be listed from June 2nd to June 5th, 2025. The company plans to globally issue 24.856 million shares, with 10% for sale in Hong Kong and 90% for international sale. The offering price is HK$9.75 per share, with a minimum subscription of 400 shares. It is expected that trading of the shares will begin on the Stock Exchange on June 10th, 2025 (Tuesday).
Latest
1 m ago
Dragon Boat Festival holiday Tianjin key commercial enterprises sales increased by 10.9% year-on-year.
2 m ago
According to reports, Gazprom PJSC, the Russian natural gas industry company, has abandoned the idea of entering the European natural gas market through Turkey.
2 m ago
Russian natural gas company Gazprom abandons entry into the European natural gas market through Turkey.
5 m ago
BioNTech (BNTX.US) continued to rise by about 8.5%, closing at $122.7. The stock surged over 18% yesterday. On the news front, Pfizer announced it had reached a milestone payment agreement with BioNTech on the new generation anti-cancer drug BNT327, with a maximum milestone payment of up to $11.1 billion. In addition, Truist Securities raised BioNTech's target price from $151 to $155, maintaining a "buy" rating.
5 m ago
BioNTech continues to rise by around 8.5% and reaches a $11 billion authorization agreement with Pfizer.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.